Indication
Epstein-Barr Virus Associated Lymphoma
3 clinical trials
4 products
Product
VRx-3996Product
ValganciclovirClinical trial
A Phase 1b/2 Open-Label, Dose Escalation & Expansion Study of Orally Administered VRx-3996 & Valganciclovir in Subjects With Epstein-Barr Virus-Associated Lymphoid MalignanciesStatus: Completed, Estimated PCD: 2023-04-01
Clinical trial
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory LymphomasStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Open-Label Individual Patient Study of Epstein-Barr Virus (EBV) Specific T-Cell Lines for the Treatment of a Lymphoproliferative Disease and Hemophagocytic Syndrome Associated With EBVStatus: Recruiting, Estimated PCD: 2025-04-05
Product
EBV-specific T cells